Goodwin advised BridgeBio Pharma on the matter. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and Kyowa Kirin Co., Ltd (TSE:4151) announced a partnership wherein BridgeBio’s affiliate, QED Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Braidwell, LP on the matter. Braidwell, LP announced the consummation of an additional investment in Nevro Corp. (NYSE: NVRO), consisting of a six-year, $200,000,000 senior...
You must be a Standard 1 Year member to access this content.
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin advised iRobot on the financing, and Latham & Watkins advised Carlyle. iRobot Corporation (NASDAQ:IRBT) announced a $200 million senior secured term loan financing provided by...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Subject Matter, and Seyfarth Shaw advised Kivvit. Subject Matter, a portfolio company of Coral Tree Partners, announced its acquisition of Kivvit to create...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter, McCarthy Tétrault and Skadden, Arps, Slate, Meagher & Flom advised Ritchie Bros. Incorporated, while Cooley and Blake, Cassels & Graydon advised IAA on the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Citrix Systems on the deal. Citrix Systems announced its acquisition by affiliates of Vista Equity Partners and Evergreen Coast Capital Corporation, an affiliate of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...
You must be a Standard 1 Year member to access this content.
